Why BiondVax Pharmaceuticals (BVXV) stock rallied today?

December 22, 2021 11:54 AM PST | By Rupam Roy

Google News:

Why BiondVax Pharmaceuticals (BVXV) stock rallied today? — Image source: Christian Delbert,Shutterstock

Recent News

DoubleVerify Sees Update in Digital Ad Tech Sector Russell 1000

Pagaya Technologies PGY Gains Support Nasdaq Index Stocks Watch

Oceaneering International OII Sees Institutional Growth on NYSE Compos...

GAMMA Expands Stake in Valvoline Inc Amid Market Movements S&P 500

Highlights

BiondVax Pharmaceuticals Ltd. has signed a definitive agreement with Max Planck Society and University Medical Center Göttingen.

BiondVax will collaborate with the two organizations to develop and commercialize Covid-19 nanosized antibodies (NanoAbs).

BiondVax stock jumped more than 127% in intraday trading.

Shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) jumped over 127% on Wednesday after announcing its collaborative project to develop nanosized Covid-19 antibodies (NanoAbs).

The Israel-based company said that it had signed a definitive agreement with Germany’s Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) to develop the drug.

Also Read: Global real-estate management firm GLP eyes US IPO

The agreement is part of a broader collaboration to be finalized in January next year. It will cover the development and commercialization of NanoAbs for various other diseases.

Also Read: Is Philly delivery startup Gopuff gearing up for IPO?

Also Read: Why Red Cat Holdings (RCAT) stocks jumped Wednesday?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) stock performance and financial highlights

The BVXV stock traded at US$3.3696 at 10:12 am ET on Dec 22, up 127.68% from its previous close. The stock fell 54.46% YTD. The stock saw the highest price of US$7.22 and the lowest price of US$1.36 in the last 52-week. Its trading volume was 86,275 on Dec 21.

The firm has a market cap of US$43.85 million. Its EPS is US$-1.12.

Also Read: Gardiner Healthcare IPO: How to buy the stock?

The company's total operating expenses were US$2.5 million in Q3, FY21. Its net loss was US$2.86 million compared to a loss of US$1.41 million in Q3, FY20.

Also Read: Yearender: Consumer stocks that created a buzz in 2021

Bottomline

The research on NanoAb is led by UMG’s molecular oncology expert Matthias Dobbelstein and Max Planck’s biophysical chemistry expert Dirk Görlich. NanoAbs showed a competitive edge over the existing Covid-19 therapies.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.